In 2025, we have seen Women’s Health and endometriosis continue to move from the margins of policy towards the core of political agendas. This shift is driving real, tangible improvements for patients and families worldwide.

Looking ahead, we expect to see maintained momentum in 2026 and onwards as these policy frameworks translate into clinical progress and improved care.

Gesynta Pharma is committed to developing improved treatments for patients with endometriosis. In 2025, our lead candidate vipoglanstat – a first-in-class, non-hormonal, and non-opioid treatment – entered clinical Phase 2 development.

Check out some of the significant policy milestones from the past year.

Australia, February:
The government allocated 573 million Australian dollars over five years for women’s health. The package includes funding for several Endometriosis and Pelvic Pain Clinics.

Portugal, March:
Employees and students with endometriosis or adenomyosis are entitled to up to three days of absence per month without loss of salary.

Germany, May:
The Federal Ministry of Research, Technology and Space boosts endometriosis research support by 140 % to € 8.5 million.

EU, July:
First-ever EU Parliament plenary session on endometriosis was held. Member States were urged to adopt or strengthen national endometriosis strategies.

Ireland, October:
Launch of Ireland's first Endometriosis Framework, creating a clear clinical care pathway for women and girls with endometriosis.

Denmark, October:
The government allocates DKK 160 million over four years for a new research center focusing on women’s health.